Yellow fever can rebound after patients seem better
Most yellow fever cases ease within five days. About fifteen percent then crash into a toxic second phase with returning fever, jaundice, and high bleeding risk. Death claims up to half of those who enter severe disease. A safe vaccine exists; once infected, care is only symptomatic.
Yellow fever is a short-course viral illness spread by mosquito bite. Early signs include fever, chills, appetite loss, nausea, backache, and headache. After an incubation of three to six days, many people clear a mild illness in the same span. In roughly fifteen percent, fever returns with abdominal pain and liver injury that yellows the skin; mouth, nose, eye, or gut bleeding may produce so-called black vomit. Among those who develop jaundice, fatality estimates run twenty to fifty percent; overall fatality is about three to seven point five percent.
The pathogen is an RNA orthoflavivirus about forty to fifty nanometers wide—the namesake of Flaviviridae—and in 1927 it became the first human virus isolated. Urban transmission leans on Aedes aegypti; forest cycles use other mosquitoes and nonhuman primates, so eradication would require wiping out vectors. Africa holds about ninety percent of an estimated two hundred thousand yearly cases. In 2013, models put African severe infections near one hundred thirty thousand with seventy-eight thousand deaths. Walter Reed’s work around 1900 showed mosquito and filtered-serum transmission.
Diagnosis mixes travel history with symptoms; confirmation needs PCR or related lab methods, and mild cases are easy to miss. Prevention rests on vaccination, mosquito control, nets, and repellents. Nearly a billion people live where the disease is common across tropical Africa and South America, though not Asia. Case counts have risen since the 1980s with falling immunity, urbanization, mobility, and climate-driven mosquito habitat. Survivors generally gain lifelong immunity without lasting organ damage.
Source: Yellow fever
